Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Depression, Postpartum | 30 | 2023 | 335 | 6.480 |
Why?
|
Pregnancy Complications | 46 | 2023 | 2867 | 6.250 |
Why?
|
Depressive Disorder, Major | 51 | 2022 | 4606 | 4.820 |
Why?
|
Antidepressive Agents | 40 | 2023 | 2836 | 3.890 |
Why?
|
Psychiatry | 21 | 2021 | 1686 | 3.360 |
Why?
|
Antipsychotic Agents | 29 | 2023 | 3055 | 3.350 |
Why?
|
Fatty Acids, Omega-3 | 27 | 2022 | 1338 | 3.050 |
Why?
|
Abnormalities, Drug-Induced | 10 | 2023 | 320 | 2.610 |
Why?
|
Puerperal Disorders | 7 | 2023 | 279 | 2.570 |
Why?
|
Mental Disorders | 30 | 2023 | 6570 | 2.490 |
Why?
|
Women's Health | 16 | 2020 | 2029 | 2.240 |
Why?
|
Complementary Therapies | 9 | 2013 | 484 | 2.230 |
Why?
|
Pregnancy | 90 | 2023 | 29002 | 2.170 |
Why?
|
Depressive Disorder | 17 | 2023 | 3743 | 1.600 |
Why?
|
Ketamine | 8 | 2022 | 498 | 1.560 |
Why?
|
Perinatal Care | 6 | 2019 | 225 | 1.460 |
Why?
|
Mood Disorders | 6 | 2023 | 1102 | 1.400 |
Why?
|
Periodicals as Topic | 6 | 2021 | 1428 | 1.390 |
Why?
|
Depression | 23 | 2023 | 7689 | 1.300 |
Why?
|
Menopause | 9 | 2017 | 1613 | 1.300 |
Why?
|
Reproduction | 4 | 2022 | 666 | 1.220 |
Why?
|
Bipolar Disorder | 17 | 2022 | 5023 | 1.150 |
Why?
|
Valproic Acid | 6 | 2022 | 444 | 1.130 |
Why?
|
Urea | 5 | 2020 | 448 | 1.130 |
Why?
|
Registries | 18 | 2023 | 8039 | 1.090 |
Why?
|
Eicosapentaenoic Acid | 7 | 2019 | 581 | 1.040 |
Why?
|
Pregnancy Outcome | 7 | 2022 | 2789 | 1.010 |
Why?
|
Mental Health | 8 | 2023 | 2946 | 1.010 |
Why?
|
Career Mobility | 4 | 2012 | 262 | 0.990 |
Why?
|
Publishing | 3 | 2024 | 828 | 0.940 |
Why?
|
Postpartum Period | 10 | 2023 | 1070 | 0.940 |
Why?
|
Hot Flashes | 7 | 2020 | 316 | 0.910 |
Why?
|
Scientific Misconduct | 1 | 2024 | 71 | 0.910 |
Why?
|
Female | 144 | 2023 | 378853 | 0.910 |
Why?
|
Docosahexaenoic Acids | 7 | 2019 | 873 | 0.910 |
Why?
|
Psychotropic Drugs | 3 | 2018 | 891 | 0.890 |
Why?
|
Antimanic Agents | 5 | 2016 | 522 | 0.850 |
Why?
|
Central Nervous System Stimulants | 4 | 2023 | 1146 | 0.850 |
Why?
|
Psychiatric Status Rating Scales | 19 | 2021 | 6028 | 0.840 |
Why?
|
Dietary Supplements | 9 | 2022 | 3279 | 0.810 |
Why?
|
Humans | 192 | 2024 | 739398 | 0.800 |
Why?
|
Infant, Newborn, Diseases | 3 | 2018 | 578 | 0.780 |
Why?
|
Psychotherapy | 7 | 2020 | 1638 | 0.780 |
Why?
|
Peer Review | 2 | 2014 | 207 | 0.780 |
Why?
|
Anxiety Disorders | 5 | 2018 | 2674 | 0.760 |
Why?
|
Piperidines | 6 | 2020 | 1597 | 0.750 |
Why?
|
Perimenopause | 4 | 2020 | 139 | 0.750 |
Why?
|
Infertility, Female | 2 | 2018 | 784 | 0.720 |
Why?
|
Anticonvulsants | 6 | 2022 | 1907 | 0.710 |
Why?
|
Psychotic Disorders | 4 | 2023 | 3028 | 0.710 |
Why?
|
Citalopram | 2 | 2017 | 404 | 0.700 |
Why?
|
Tetrahydrofolates | 1 | 2019 | 61 | 0.660 |
Why?
|
Methylphenidate | 2 | 2023 | 473 | 0.650 |
Why?
|
S-Adenosylmethionine | 5 | 2013 | 212 | 0.650 |
Why?
|
Clinical Trials as Topic | 11 | 2017 | 7897 | 0.630 |
Why?
|
Deception | 1 | 2019 | 103 | 0.630 |
Why?
|
Fish Oils | 3 | 2011 | 469 | 0.610 |
Why?
|
Sertraline | 2 | 2009 | 206 | 0.610 |
Why?
|
Anxiety | 9 | 2023 | 4253 | 0.610 |
Why?
|
Adult | 76 | 2023 | 213394 | 0.610 |
Why?
|
Norepinephrine | 1 | 2020 | 910 | 0.600 |
Why?
|
Benzodiazepines | 4 | 2022 | 1099 | 0.600 |
Why?
|
Sulfides | 1 | 2017 | 166 | 0.580 |
Why?
|
Piperazines | 3 | 2017 | 2480 | 0.560 |
Why?
|
Estrogens | 3 | 2013 | 1561 | 0.560 |
Why?
|
Interview, Psychological | 2 | 2017 | 812 | 0.560 |
Why?
|
Drug Labeling | 1 | 2018 | 230 | 0.550 |
Why?
|
Peer Review, Research | 2 | 2009 | 327 | 0.550 |
Why?
|
Pregnancy Trimester, First | 7 | 2023 | 847 | 0.550 |
Why?
|
Double-Blind Method | 23 | 2023 | 11985 | 0.540 |
Why?
|
Psychotherapy, Brief | 2 | 2014 | 114 | 0.540 |
Why?
|
Serotonin | 2 | 2020 | 1022 | 0.540 |
Why?
|
Attention Deficit Disorder with Hyperactivity | 4 | 2023 | 3636 | 0.530 |
Why?
|
Prenatal Care | 3 | 2019 | 1087 | 0.530 |
Why?
|
Research | 5 | 2018 | 2001 | 0.520 |
Why?
|
Stress, Psychological | 4 | 2021 | 4212 | 0.510 |
Why?
|
Treatment Outcome | 42 | 2023 | 62693 | 0.510 |
Why?
|
Hostility | 1 | 2015 | 189 | 0.500 |
Why?
|
Paroxetine | 3 | 2012 | 182 | 0.500 |
Why?
|
Premenopause | 1 | 2019 | 1028 | 0.490 |
Why?
|
Breast Feeding | 5 | 2021 | 1334 | 0.490 |
Why?
|
Cyclopropanes | 1 | 2016 | 421 | 0.490 |
Why?
|
Antidepressive Agents, Second-Generation | 2 | 2009 | 503 | 0.490 |
Why?
|
Lithium | 4 | 2005 | 603 | 0.480 |
Why?
|
Mothers | 5 | 2023 | 2143 | 0.470 |
Why?
|
Object Attachment | 2 | 2014 | 312 | 0.470 |
Why?
|
Reproductive Techniques, Assisted | 1 | 2018 | 483 | 0.470 |
Why?
|
Postmenopause | 3 | 2020 | 2456 | 0.470 |
Why?
|
Family Planning Services | 1 | 2016 | 246 | 0.460 |
Why?
|
Placebo Effect | 1 | 2017 | 503 | 0.450 |
Why?
|
Anger | 1 | 2015 | 401 | 0.450 |
Why?
|
Mass Screening | 7 | 2023 | 5265 | 0.440 |
Why?
|
Hypericum | 5 | 2013 | 58 | 0.440 |
Why?
|
Phytotherapy | 3 | 2010 | 298 | 0.430 |
Why?
|
Time Management | 1 | 2012 | 50 | 0.430 |
Why?
|
Mother-Child Relations | 2 | 2014 | 479 | 0.430 |
Why?
|
Contraception | 1 | 2016 | 344 | 0.430 |
Why?
|
Phototherapy | 6 | 2013 | 372 | 0.430 |
Why?
|
Drug Monitoring | 3 | 2015 | 961 | 0.420 |
Why?
|
Peripartum Period | 1 | 2013 | 134 | 0.420 |
Why?
|
Child Rearing | 1 | 2012 | 74 | 0.420 |
Why?
|
Hypertriglyceridemia | 1 | 2015 | 294 | 0.420 |
Why?
|
Aminopyridines | 1 | 2015 | 541 | 0.410 |
Why?
|
Fatigue | 2 | 2016 | 1524 | 0.410 |
Why?
|
Patient Selection | 5 | 2017 | 4211 | 0.410 |
Why?
|
Women, Working | 1 | 2012 | 87 | 0.400 |
Why?
|
Pre-Eclampsia | 2 | 2018 | 1194 | 0.400 |
Why?
|
Secondary Prevention | 4 | 2020 | 1516 | 0.390 |
Why?
|
Hospitals, General | 6 | 2023 | 744 | 0.390 |
Why?
|
Capsules | 1 | 2011 | 199 | 0.390 |
Why?
|
Community Mental Health Services | 1 | 2014 | 385 | 0.390 |
Why?
|
Altruism | 1 | 2013 | 204 | 0.380 |
Why?
|
Patient Acceptance of Health Care | 2 | 2014 | 3021 | 0.370 |
Why?
|
Taste | 1 | 2011 | 175 | 0.370 |
Why?
|
United States Food and Drug Administration | 1 | 2018 | 1584 | 0.370 |
Why?
|
Dysthymic Disorder | 1 | 2010 | 74 | 0.360 |
Why?
|
Mentors | 3 | 2012 | 632 | 0.360 |
Why?
|
Biomedical Research | 4 | 2021 | 3301 | 0.350 |
Why?
|
Women | 1 | 2011 | 230 | 0.350 |
Why?
|
Sex Characteristics | 2 | 2019 | 2583 | 0.350 |
Why?
|
Cesarean Section | 1 | 2018 | 1371 | 0.350 |
Why?
|
Middle Aged | 44 | 2022 | 212863 | 0.340 |
Why?
|
Gestational Age | 3 | 2016 | 3486 | 0.340 |
Why?
|
Young Adult | 23 | 2022 | 56255 | 0.340 |
Why?
|
Nortriptyline | 1 | 2009 | 80 | 0.340 |
Why?
|
Motivation | 1 | 2019 | 1965 | 0.330 |
Why?
|
Lithium Compounds | 2 | 2009 | 225 | 0.330 |
Why?
|
Acupuncture Therapy | 5 | 2013 | 462 | 0.320 |
Why?
|
Thiophenes | 1 | 2013 | 589 | 0.320 |
Why?
|
Hypercholesterolemia | 1 | 2015 | 1143 | 0.320 |
Why?
|
Perinatology | 1 | 2008 | 60 | 0.310 |
Why?
|
Dose-Response Relationship, Drug | 9 | 2020 | 10945 | 0.310 |
Why?
|
Premature Birth | 2 | 2023 | 1702 | 0.310 |
Why?
|
Massachusetts | 9 | 2023 | 8669 | 0.300 |
Why?
|
Dibenzothiazepines | 2 | 2007 | 104 | 0.300 |
Why?
|
Child, Hospitalized | 1 | 2009 | 175 | 0.300 |
Why?
|
Carbamazepine | 4 | 2014 | 229 | 0.300 |
Why?
|
Prospective Studies | 17 | 2023 | 53037 | 0.300 |
Why?
|
Vitamins | 1 | 2015 | 1602 | 0.290 |
Why?
|
Drug Therapy, Combination | 12 | 2022 | 6478 | 0.290 |
Why?
|
Pregnant Women | 3 | 2023 | 558 | 0.290 |
Why?
|
Electronic Mail | 1 | 2009 | 214 | 0.290 |
Why?
|
Risperidone | 3 | 2007 | 383 | 0.290 |
Why?
|
Review Literature as Topic | 1 | 2009 | 328 | 0.290 |
Why?
|
Gender Identity | 1 | 2012 | 674 | 0.290 |
Why?
|
Nutrition Assessment | 1 | 2010 | 717 | 0.290 |
Why?
|
Reproductive Medicine | 1 | 2008 | 108 | 0.290 |
Why?
|
Randomized Controlled Trials as Topic | 10 | 2016 | 9812 | 0.280 |
Why?
|
Combined Modality Therapy | 7 | 2018 | 8605 | 0.280 |
Why?
|
Recurrence | 8 | 2020 | 8307 | 0.280 |
Why?
|
Physicians, Women | 1 | 2012 | 483 | 0.280 |
Why?
|
Pregnancy Trimester, Third | 1 | 2008 | 568 | 0.280 |
Why?
|
Body Mass Index | 3 | 2020 | 12655 | 0.270 |
Why?
|
Pregnancy Trimester, Second | 1 | 2008 | 732 | 0.270 |
Why?
|
Infant Welfare | 1 | 2005 | 82 | 0.270 |
Why?
|
Fertilization in Vitro | 1 | 2013 | 1283 | 0.270 |
Why?
|
Faculty | 1 | 2008 | 376 | 0.260 |
Why?
|
Referral and Consultation | 3 | 2014 | 3514 | 0.260 |
Why?
|
Advisory Committees | 3 | 2019 | 770 | 0.250 |
Why?
|
Terminology as Topic | 2 | 2009 | 1548 | 0.250 |
Why?
|
Disease Susceptibility | 1 | 2011 | 1778 | 0.250 |
Why?
|
Sudden Infant Death | 1 | 2007 | 291 | 0.250 |
Why?
|
Pandemics | 3 | 2023 | 8274 | 0.250 |
Why?
|
Risk Factors | 17 | 2023 | 71974 | 0.240 |
Why?
|
Affect | 4 | 2023 | 1475 | 0.240 |
Why?
|
Cognition | 4 | 2017 | 6686 | 0.240 |
Why?
|
Adolescent | 18 | 2022 | 85405 | 0.230 |
Why?
|
Postnatal Care | 1 | 2005 | 233 | 0.230 |
Why?
|
Hypertension, Pulmonary | 1 | 2014 | 1525 | 0.230 |
Why?
|
Leuprolide | 2 | 2016 | 303 | 0.230 |
Why?
|
Vitamin D | 2 | 2022 | 3197 | 0.220 |
Why?
|
United States | 18 | 2021 | 69573 | 0.220 |
Why?
|
Placebos | 5 | 2014 | 1678 | 0.220 |
Why?
|
Leadership | 1 | 2012 | 1349 | 0.220 |
Why?
|
Testosterone | 2 | 2004 | 2391 | 0.220 |
Why?
|
Premenstrual Syndrome | 2 | 2017 | 109 | 0.220 |
Why?
|
Parturition | 2 | 2023 | 431 | 0.210 |
Why?
|
Biological Psychiatry | 1 | 2022 | 25 | 0.210 |
Why?
|
Folic Acid | 4 | 2016 | 1297 | 0.210 |
Why?
|
Obstetrics | 1 | 2009 | 660 | 0.210 |
Why?
|
Nasal Sprays | 1 | 2022 | 19 | 0.210 |
Why?
|
Career Choice | 1 | 2008 | 742 | 0.210 |
Why?
|
Infant, Newborn | 10 | 2023 | 25470 | 0.210 |
Why?
|
Buspirone | 1 | 2022 | 82 | 0.210 |
Why?
|
Conflict of Interest | 1 | 2007 | 541 | 0.210 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3143 | 0.210 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3248 | 0.200 |
Why?
|
Clozapine | 3 | 2003 | 498 | 0.200 |
Why?
|
Disease Progression | 1 | 2018 | 13237 | 0.200 |
Why?
|
Comorbidity | 7 | 2017 | 10362 | 0.200 |
Why?
|
Sexual Behavior | 2 | 2009 | 2040 | 0.200 |
Why?
|
Cyclohexanecarboxylic Acids | 2 | 2003 | 143 | 0.200 |
Why?
|
Dyskinesia, Drug-Induced | 1 | 2002 | 164 | 0.200 |
Why?
|
Mental Health Services | 2 | 2020 | 1641 | 0.200 |
Why?
|
Serotonin 5-HT2 Receptor Antagonists | 1 | 2020 | 21 | 0.200 |
Why?
|
Tachyphylaxis | 2 | 2018 | 51 | 0.190 |
Why?
|
Prenatal Exposure Delayed Effects | 3 | 2022 | 2393 | 0.190 |
Why?
|
Luteal Phase | 1 | 2021 | 147 | 0.190 |
Why?
|
Estradiol | 2 | 2020 | 2021 | 0.190 |
Why?
|
Amines | 2 | 2003 | 277 | 0.190 |
Why?
|
Male | 34 | 2022 | 349022 | 0.190 |
Why?
|
Drug Industry | 1 | 2007 | 742 | 0.190 |
Why?
|
Diagnostic and Statistical Manual of Mental Disorders | 4 | 2014 | 1951 | 0.180 |
Why?
|
Obesity | 2 | 2020 | 12643 | 0.180 |
Why?
|
Sex Factors | 7 | 2013 | 10398 | 0.180 |
Why?
|
Child Health Services | 1 | 2005 | 665 | 0.180 |
Why?
|
Herbal Medicine | 2 | 2010 | 36 | 0.170 |
Why?
|
Menarche | 1 | 2002 | 513 | 0.170 |
Why?
|
Awareness | 1 | 2023 | 639 | 0.170 |
Why?
|
Longevity | 2 | 2023 | 1066 | 0.170 |
Why?
|
Suicidal Ideation | 3 | 2023 | 1236 | 0.170 |
Why?
|
Exercise | 3 | 2014 | 5591 | 0.170 |
Why?
|
Receptors, Opioid, kappa | 1 | 2020 | 144 | 0.160 |
Why?
|
Adaptation, Psychological | 2 | 2023 | 2564 | 0.160 |
Why?
|
Anniversaries and Special Events | 1 | 2019 | 89 | 0.160 |
Why?
|
Cooperative Behavior | 1 | 2005 | 1503 | 0.160 |
Why?
|
Pyrrolidines | 1 | 2020 | 342 | 0.150 |
Why?
|
Evidence-Based Medicine | 2 | 2009 | 3606 | 0.150 |
Why?
|
Drug Administration Schedule | 3 | 2018 | 4935 | 0.150 |
Why?
|
Magnetic Field Therapy | 1 | 2017 | 28 | 0.150 |
Why?
|
Eligibility Determination | 2 | 2019 | 403 | 0.150 |
Why?
|
Feeding Behavior | 1 | 2010 | 3180 | 0.150 |
Why?
|
Infant | 8 | 2023 | 34923 | 0.150 |
Why?
|
Suicide | 2 | 2023 | 1469 | 0.150 |
Why?
|
Delayed-Action Preparations | 2 | 2016 | 962 | 0.150 |
Why?
|
Schizophrenia, Paranoid | 1 | 2017 | 104 | 0.150 |
Why?
|
Ethinyl Estradiol | 1 | 2017 | 116 | 0.150 |
Why?
|
Professional Role | 1 | 2020 | 305 | 0.150 |
Why?
|
Triazines | 3 | 2016 | 316 | 0.150 |
Why?
|
Sexual Dysfunction, Physiological | 1 | 2020 | 357 | 0.140 |
Why?
|
Androstenes | 1 | 2017 | 168 | 0.140 |
Why?
|
Case-Control Studies | 4 | 2021 | 21694 | 0.140 |
Why?
|
Androgens | 1 | 2004 | 1270 | 0.140 |
Why?
|
Texas | 2 | 2014 | 394 | 0.140 |
Why?
|
gamma-Aminobutyric Acid | 2 | 2003 | 1127 | 0.140 |
Why?
|
Pilot Projects | 4 | 2014 | 8275 | 0.140 |
Why?
|
Severity of Illness Index | 5 | 2014 | 15511 | 0.130 |
Why?
|
Infusions, Intravenous | 4 | 2022 | 2270 | 0.130 |
Why?
|
Progesterone | 1 | 2020 | 772 | 0.130 |
Why?
|
Physician-Patient Relations | 1 | 2009 | 3217 | 0.130 |
Why?
|
Lactation | 2 | 2009 | 410 | 0.130 |
Why?
|
Narcotic Antagonists | 1 | 2020 | 562 | 0.130 |
Why?
|
Parents | 1 | 2009 | 3368 | 0.130 |
Why?
|
Arizona | 2 | 2005 | 106 | 0.130 |
Why?
|
Midazolam | 3 | 2022 | 270 | 0.130 |
Why?
|
Exercise Therapy | 4 | 2013 | 897 | 0.130 |
Why?
|
Biomarkers, Pharmacological | 1 | 2015 | 163 | 0.130 |
Why?
|
Chemistry, Pharmaceutical | 1 | 2016 | 285 | 0.130 |
Why?
|
Attitude of Health Personnel | 1 | 2009 | 3844 | 0.130 |
Why?
|
Weight Gain | 2 | 2020 | 2278 | 0.130 |
Why?
|
Personality Disorders | 2 | 2009 | 708 | 0.120 |
Why?
|
Milk, Human | 2 | 2009 | 490 | 0.120 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2003 | 1497 | 0.120 |
Why?
|
Feasibility Studies | 2 | 2014 | 5058 | 0.120 |
Why?
|
Benzamides | 1 | 2020 | 1374 | 0.120 |
Why?
|
Patient Care | 1 | 2020 | 638 | 0.120 |
Why?
|
Psychological Techniques | 1 | 2013 | 45 | 0.120 |
Why?
|
Psychopharmacology | 1 | 2015 | 143 | 0.110 |
Why?
|
Massage | 1 | 2013 | 85 | 0.110 |
Why?
|
Fertilization | 1 | 2014 | 196 | 0.110 |
Why?
|
Life Style | 2 | 2008 | 3817 | 0.110 |
Why?
|
National Institutes of Health (U.S.) | 2 | 2009 | 780 | 0.110 |
Why?
|
Neuropsychological Tests | 2 | 2017 | 6963 | 0.110 |
Why?
|
Nutritional Physiological Phenomena | 1 | 2015 | 370 | 0.110 |
Why?
|
Thinking | 1 | 2016 | 320 | 0.110 |
Why?
|
Risk Assessment | 5 | 2018 | 23294 | 0.110 |
Why?
|
Schizophrenia | 2 | 2002 | 6866 | 0.110 |
Why?
|
Contraceptives, Oral | 2 | 2007 | 563 | 0.110 |
Why?
|
Persistent Fetal Circulation Syndrome | 1 | 2012 | 79 | 0.110 |
Why?
|
Affective Disorders, Psychotic | 1 | 2013 | 191 | 0.110 |
Why?
|
Interprofessional Relations | 2 | 2009 | 1008 | 0.110 |
Why?
|
Bupropion | 1 | 2014 | 303 | 0.110 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2016 | 812 | 0.100 |
Why?
|
Gravidity | 2 | 2002 | 51 | 0.100 |
Why?
|
Drug Storage | 1 | 2011 | 52 | 0.100 |
Why?
|
Drug Substitution | 1 | 2014 | 283 | 0.100 |
Why?
|
Longitudinal Studies | 3 | 2020 | 13880 | 0.100 |
Why?
|
Child Care | 1 | 2012 | 119 | 0.100 |
Why?
|
Synaptic Membranes | 1 | 2011 | 87 | 0.100 |
Why?
|
Practice Guidelines as Topic | 3 | 2018 | 7274 | 0.100 |
Why?
|
Patient Compliance | 2 | 2013 | 2679 | 0.100 |
Why?
|
Hypolipidemic Agents | 1 | 2015 | 606 | 0.090 |
Why?
|
Certification | 1 | 2014 | 424 | 0.090 |
Why?
|
Remission Induction | 1 | 2016 | 2378 | 0.090 |
Why?
|
Gonadotropin-Releasing Hormone | 1 | 2016 | 1187 | 0.090 |
Why?
|
Half-Life | 1 | 2011 | 658 | 0.090 |
Why?
|
Drug Combinations | 1 | 2015 | 1959 | 0.090 |
Why?
|
Withholding Treatment | 1 | 2014 | 596 | 0.090 |
Why?
|
Benzhydryl Compounds | 1 | 2016 | 819 | 0.090 |
Why?
|
Physicians | 1 | 2008 | 4539 | 0.090 |
Why?
|
Plant Preparations | 1 | 2010 | 94 | 0.090 |
Why?
|
1-Naphthylamine | 1 | 2008 | 49 | 0.080 |
Why?
|
Maternal-Fetal Exchange | 1 | 2011 | 454 | 0.080 |
Why?
|
Overweight | 1 | 2020 | 2355 | 0.080 |
Why?
|
Nutritional Requirements | 1 | 2010 | 283 | 0.080 |
Why?
|
Parity | 2 | 2002 | 930 | 0.080 |
Why?
|
Belgium | 1 | 2008 | 103 | 0.080 |
Why?
|
Patient Education as Topic | 1 | 2018 | 2275 | 0.080 |
Why?
|
Aged | 12 | 2020 | 162698 | 0.080 |
Why?
|
Journal Impact Factor | 1 | 2009 | 155 | 0.080 |
Why?
|
Work Schedule Tolerance | 1 | 2012 | 565 | 0.080 |
Why?
|
Cold Temperature | 1 | 2011 | 775 | 0.080 |
Why?
|
Time Factors | 3 | 2016 | 40050 | 0.080 |
Why?
|
Methionine | 1 | 2010 | 591 | 0.080 |
Why?
|
Electroconvulsive Therapy | 2 | 2005 | 469 | 0.080 |
Why?
|
Diabetes, Gestational | 1 | 2017 | 1174 | 0.080 |
Why?
|
Medical History Taking | 1 | 2011 | 782 | 0.080 |
Why?
|
Triglycerides | 1 | 2015 | 2447 | 0.080 |
Why?
|
Canada | 2 | 2023 | 2021 | 0.070 |
Why?
|
Nonprescription Drugs | 1 | 2008 | 116 | 0.070 |
Why?
|
Meditation | 1 | 2010 | 242 | 0.070 |
Why?
|
Pregnancy, Unplanned | 1 | 2007 | 84 | 0.070 |
Why?
|
Personality Inventory | 1 | 2010 | 1026 | 0.070 |
Why?
|
Pharmaceutical Services | 1 | 2008 | 140 | 0.070 |
Why?
|
Organizational Policy | 1 | 2009 | 428 | 0.070 |
Why?
|
Sample Size | 1 | 2010 | 845 | 0.070 |
Why?
|
Activities of Daily Living | 1 | 2016 | 2410 | 0.070 |
Why?
|
Health Personnel | 1 | 2020 | 3203 | 0.070 |
Why?
|
Serotonin Plasma Membrane Transport Proteins | 1 | 2008 | 323 | 0.070 |
Why?
|
Food Preferences | 1 | 2010 | 398 | 0.070 |
Why?
|
Social Environment | 2 | 2008 | 1014 | 0.070 |
Why?
|
Cholesterol | 1 | 2015 | 2900 | 0.070 |
Why?
|
Birth Weight | 1 | 2014 | 2062 | 0.070 |
Why?
|
Societies, Medical | 3 | 2019 | 3739 | 0.070 |
Why?
|
Research Design | 4 | 2013 | 5959 | 0.070 |
Why?
|
Fatty Acids, Omega-6 | 1 | 2007 | 227 | 0.070 |
Why?
|
Self Report | 1 | 2017 | 3524 | 0.070 |
Why?
|
Maternal Behavior | 1 | 2008 | 311 | 0.070 |
Why?
|
Catecholamines | 1 | 2006 | 387 | 0.070 |
Why?
|
Program Evaluation | 1 | 2014 | 2484 | 0.070 |
Why?
|
Tremor | 1 | 2006 | 177 | 0.070 |
Why?
|
Patient Dropouts | 1 | 2007 | 419 | 0.060 |
Why?
|
Drug Utilization | 1 | 2011 | 1181 | 0.060 |
Why?
|
Plant Extracts | 1 | 2008 | 464 | 0.060 |
Why?
|
Drug Therapy | 1 | 2008 | 497 | 0.060 |
Why?
|
Sex Distribution | 2 | 2008 | 2296 | 0.060 |
Why?
|
Tryptophan | 1 | 2006 | 477 | 0.060 |
Why?
|
5-Hydroxytryptophan | 1 | 2004 | 32 | 0.060 |
Why?
|
Neurogenesis | 1 | 2011 | 821 | 0.060 |
Why?
|
Health Services Needs and Demand | 1 | 2012 | 1409 | 0.060 |
Why?
|
Pregnanes | 1 | 2023 | 7 | 0.060 |
Why?
|
Brain | 1 | 2011 | 26345 | 0.060 |
Why?
|
Patient Protection and Affordable Care Act | 1 | 2014 | 1206 | 0.060 |
Why?
|
Libido | 1 | 2004 | 121 | 0.060 |
Why?
|
Data Interpretation, Statistical | 1 | 2013 | 2716 | 0.060 |
Why?
|
Netherlands | 1 | 2008 | 2169 | 0.060 |
Why?
|
Epidemiologic Studies | 1 | 2006 | 677 | 0.060 |
Why?
|
Pirenzepine | 1 | 2003 | 115 | 0.060 |
Why?
|
Treatment Refusal | 1 | 2006 | 419 | 0.060 |
Why?
|
Follow-Up Studies | 3 | 2022 | 38942 | 0.050 |
Why?
|
Telemedicine | 1 | 2020 | 2844 | 0.050 |
Why?
|
Socioeconomic Factors | 1 | 2016 | 7726 | 0.050 |
Why?
|
Child | 6 | 2023 | 77033 | 0.050 |
Why?
|
Lithium Carbonate | 1 | 2003 | 184 | 0.050 |
Why?
|
Tissue Distribution | 1 | 2006 | 2345 | 0.050 |
Why?
|
Climacteric | 1 | 2002 | 57 | 0.050 |
Why?
|
Research Support as Topic | 1 | 2007 | 706 | 0.050 |
Why?
|
Choice Behavior | 1 | 2008 | 801 | 0.050 |
Why?
|
Amphetamine | 1 | 2023 | 225 | 0.050 |
Why?
|
Social Support | 1 | 2011 | 2112 | 0.050 |
Why?
|
Huntington Disease | 1 | 2008 | 1109 | 0.050 |
Why?
|
History, 21st Century | 1 | 2008 | 1534 | 0.050 |
Why?
|
Folic Acid Deficiency | 1 | 2002 | 116 | 0.050 |
Why?
|
Injections, Intramuscular | 1 | 2003 | 546 | 0.050 |
Why?
|
Program Development | 1 | 2008 | 1313 | 0.050 |
Why?
|
Stress Disorders, Post-Traumatic | 2 | 2009 | 4220 | 0.050 |
Why?
|
Polycystic Ovary Syndrome | 1 | 2005 | 365 | 0.050 |
Why?
|
Self-Injurious Behavior | 1 | 2007 | 461 | 0.050 |
Why?
|
Fructose | 1 | 2003 | 287 | 0.050 |
Why?
|
Hypothyroidism | 1 | 2006 | 659 | 0.050 |
Why?
|
Acetates | 2 | 2003 | 313 | 0.050 |
Why?
|
Causality | 1 | 2007 | 1262 | 0.050 |
Why?
|
Interpersonal Relations | 1 | 2008 | 1421 | 0.050 |
Why?
|
Neural Tube Defects | 1 | 2002 | 253 | 0.050 |
Why?
|
Yoga | 2 | 2014 | 253 | 0.050 |
Why?
|
Prejudice | 1 | 2004 | 572 | 0.050 |
Why?
|
History, 20th Century | 1 | 2008 | 2742 | 0.040 |
Why?
|
Cognition Disorders | 1 | 2014 | 4026 | 0.040 |
Why?
|
Feedback | 1 | 2023 | 788 | 0.040 |
Why?
|
Vasomotor System | 1 | 2020 | 210 | 0.040 |
Why?
|
Family Health | 1 | 2004 | 1281 | 0.040 |
Why?
|
Ovulation | 1 | 2020 | 190 | 0.040 |
Why?
|
Calcium Channel Blockers | 2 | 2003 | 686 | 0.040 |
Why?
|
Drug Prescriptions | 1 | 2008 | 1637 | 0.040 |
Why?
|
Psychomotor Performance | 1 | 2006 | 1899 | 0.040 |
Why?
|
Body Weight | 1 | 2008 | 4660 | 0.040 |
Why?
|
Obsessive-Compulsive Disorder | 1 | 2007 | 1442 | 0.040 |
Why?
|
Zinc | 1 | 2022 | 683 | 0.040 |
Why?
|
Guidelines as Topic | 1 | 2004 | 1407 | 0.040 |
Why?
|
Single-Blind Method | 1 | 2021 | 1585 | 0.040 |
Why?
|
Body Image | 1 | 2022 | 608 | 0.040 |
Why?
|
Prevalence | 2 | 2005 | 15153 | 0.040 |
Why?
|
Delphi Technique | 1 | 2020 | 770 | 0.040 |
Why?
|
Contraceptives, Oral, Combined | 1 | 2017 | 113 | 0.040 |
Why?
|
Diet | 1 | 2015 | 7876 | 0.040 |
Why?
|
Waist Circumference | 1 | 2020 | 912 | 0.040 |
Why?
|
Fatty Acids, Unsaturated | 1 | 2020 | 547 | 0.040 |
Why?
|
Fertility Agents, Female | 1 | 2016 | 99 | 0.040 |
Why?
|
Hormone Replacement Therapy | 1 | 2002 | 740 | 0.030 |
Why?
|
Arrhythmias, Cardiac | 1 | 2006 | 2265 | 0.030 |
Why?
|
Attitude to Health | 1 | 2005 | 2047 | 0.030 |
Why?
|
Prognosis | 2 | 2010 | 28901 | 0.030 |
Why?
|
Patient Satisfaction | 1 | 2008 | 3382 | 0.030 |
Why?
|
Diagnosis, Differential | 2 | 2002 | 12948 | 0.030 |
Why?
|
Models, Psychological | 1 | 1999 | 809 | 0.030 |
Why?
|
Age of Onset | 1 | 2002 | 3263 | 0.030 |
Why?
|
Qualitative Research | 1 | 2023 | 2656 | 0.030 |
Why?
|
Random Allocation | 1 | 2019 | 2417 | 0.030 |
Why?
|
Pregnancy Trimesters | 1 | 2015 | 192 | 0.030 |
Why?
|
Cross-Sectional Studies | 2 | 2022 | 24714 | 0.030 |
Why?
|
Forecasting | 1 | 2023 | 2952 | 0.030 |
Why?
|
Cross-Over Studies | 1 | 1999 | 2030 | 0.030 |
Why?
|
Genotype | 1 | 2008 | 12951 | 0.030 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2008 | 3908 | 0.030 |
Why?
|
Pyrazoles | 1 | 2023 | 1963 | 0.030 |
Why?
|
Caregivers | 1 | 2004 | 2067 | 0.030 |
Why?
|
Acute Disease | 1 | 2002 | 7128 | 0.020 |
Why?
|
Decision Making | 1 | 2005 | 3854 | 0.020 |
Why?
|
Inflammation | 1 | 2011 | 10534 | 0.020 |
Why?
|
Consensus | 1 | 2020 | 2913 | 0.020 |
Why?
|
Linear Models | 1 | 2020 | 5948 | 0.020 |
Why?
|
Schizophrenic Psychology | 1 | 2017 | 1677 | 0.020 |
Why?
|
Signal Transduction | 2 | 2011 | 23355 | 0.020 |
Why?
|
Animals | 2 | 2011 | 168368 | 0.020 |
Why?
|
Smoking | 1 | 2005 | 8960 | 0.020 |
Why?
|
Women's Health Services | 1 | 2008 | 93 | 0.020 |
Why?
|
Glycosides | 1 | 2008 | 106 | 0.020 |
Why?
|
Health Care Surveys | 1 | 2015 | 2448 | 0.020 |
Why?
|
Reproducibility of Results | 1 | 2005 | 19811 | 0.020 |
Why?
|
Quality of Life | 1 | 2008 | 12640 | 0.020 |
Why?
|
Drug Resistance | 1 | 2011 | 1610 | 0.020 |
Why?
|
Sleep Initiation and Maintenance Disorders | 1 | 2014 | 993 | 0.020 |
Why?
|
Health Services Accessibility | 1 | 2021 | 5128 | 0.020 |
Why?
|
Aged, 80 and over | 1 | 2009 | 57650 | 0.010 |
Why?
|
Indans | 1 | 2003 | 96 | 0.010 |
Why?
|
Confidence Intervals | 1 | 2008 | 2974 | 0.010 |
Why?
|
Age Distribution | 1 | 2008 | 2904 | 0.010 |
Why?
|
Primary Prevention | 1 | 2008 | 1165 | 0.010 |
Why?
|
Synaptic Transmission | 1 | 2006 | 1177 | 0.010 |
Why?
|
Cost-Benefit Analysis | 1 | 2013 | 5462 | 0.010 |
Why?
|
Cohort Studies | 1 | 2002 | 40389 | 0.010 |
Why?
|
Antihypertensive Agents | 1 | 2008 | 2039 | 0.010 |
Why?
|
Sleep | 1 | 2014 | 4596 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2006 | 6370 | 0.010 |
Why?
|
Thiazoles | 1 | 2003 | 1488 | 0.010 |
Why?
|
Odds Ratio | 1 | 2008 | 9846 | 0.010 |
Why?
|
Anticoagulants | 1 | 2008 | 4582 | 0.010 |
Why?
|
Anti-Bacterial Agents | 1 | 2008 | 7136 | 0.010 |
Why?
|
Retrospective Studies | 1 | 2006 | 76631 | 0.000 |
Why?
|